A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This phase 2, multicenter, two-part, open-label, single-arm study will be conducted in Japan
and will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of
pexidartinib in adult participants with symptomatic tenosynovial giant cell tumor (TGCT)
associated with severe morbidity or functional limitation and not amenable to improvement
with surgery.